Amplia Therapeutics Ltd (ASX:ATX)'s Dr John Lambert discusses with Proactive a positive outcome from a pre-Investigational New Drug (pre-IND) meeting with the United States Food and Drug Administration (FDA) Division of Oncologic Diseases. The company sought feedback from the FDA on development plans for a clinical trial investigating Amplia’s focal adhesion kinase inhibitor, AMP945, in people with pancreatic cancer.
Amplia Therapeutics welcomes positive FDA feedback on AMP945 development
